Physician profile
Nancy Chen
NPI 1346219946
$2,308.35
in general payments reported to CMS, 2019-2025
14 companies · $567 in 2025
The $567 reported for 2025 was more than what 81% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79.20 · 2020: $127 · 2021: $132 · 2022: $223 · 2023: $509 · 2024: $671 · 2025: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,541 · Education: $207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,540.53 |
| Education | $207.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $611.31 | 2020-2025 | Tremfya, Stelara, Remicade |
| Abbvie INC. | $419.60 | 2019-2025 | Rinvoq |
| Ucb, INC. | $310.94 | 2024-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $261.51 | 2022-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $194.57 | 2023-2024 | Sotyktu |
| Pfizer INC. | $186.06 | 2020-2023 | |
| Vyne Pharmaceuticals INC. | $132.50 | 2020-2021 | |
| Lilly USA, LLC | $45.28 | 2021-2024 | Taltz, Olumiant |
| Galderma Laboratories, L.P. | $35.98 | 2020-2025 | Nemluvio |
| Incyte Corporation | $31.83 | 2022-2024 | Opzelura |
| Genzyme Corporation | $30.57 | 2023 | |
| Organon LLC | $29.73 | 2025 | Vtama |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Biofrontera INC. | $5.30 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.